Gilead Sciences to close Seattle office
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
Hosted on MSN18h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City, ...
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Gilead’s bread and butter has been ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...
Wolfe Research initiated coverage of Gilead (GILD) with an Outperform rating and $110 price target Published first on TheFly – the ...
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance. The quarter saw substantial revenue growth, encouraging confidence in ...
Gilead Sciences (GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from its COVID revenues and spurring investor anticipation for new products ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback